Status:
RECRUITING
Tumor-Derived FGF19
Lead Sponsor:
University of Central Florida
Conditions:
Colorectal Cancer
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Identify and test thresholds, specificity and sensitivity for a potential cancer associated biomarker protein, FGF19, (and associated markers) for detection in human blood in the blood of breast and c...
Detailed Description
This project seeks to develop and test a more convenient detection modality for colorectal cancer and to test feasibility for breast cancer screening through a blood based test for cancer detection. B...
Eligibility Criteria
Inclusion
- The study will enroll adult persons with breast cancer or colorectal cancer or no cancer (healthy controls) who are able to do a fasting blood draw.
- (Pregnant women may choose to be in the study. The study procedures do not pose a risk to the safety of the unborn child or the woman.)
Exclusion
- The study will not enroll persons who are unable or unwilling to provide informed consent.
- Adults unable to consent, individuals who are not yet adults, and prisoners will be excluded from this study.
Key Trial Info
Start Date :
June 6 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT06068257
Start Date
June 6 2023
End Date
June 1 2025
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Burnett School Biomedical Sciences
Orlando, Florida, United States, 32816